You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. CORPORATE - 07-03-2016

    CURhE, Global Alliance for mother and child healthcare

    Kedrion among the founding members. The aim is Rh disease eradication

    read more 
  2. CORPORATE - 19-01-2016

    Kedrion Biopharma strengthens its position on the US market

    Granted exclusive rights to commercialize a lifesaving drug in the US

    read more 
  3. CORPORATE - 18-01-2016

    A brand new location for KEDPlasma donors in the very center of Fürth

    Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide

    read more 
  4. CORPORATE - 08-01-2016

    KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US

    The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma

    read more 

Pages

For more information please contact: pressoffice@kedrion.com